GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
- Conditions
- Migraine Disorders
- Interventions
- Drug: Combination Product (sumatriptan succinate / naproxen sodium)Drug: Placebo
- First Posted Date
- 2006-10-02
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 173
- Registration Number
- NCT00383162
- Locations
- 🇺🇸
GSK Investigational Site, Virginia Beach, Virginia, United States
Study to Assess GW642444 in Asthma Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GW642444MDrug: GW642444HOther: placebo
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00381667
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa
- Conditions
- Parkinson Disease
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 393
- Registration Number
- NCT00381472
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT00381238
- Locations
- 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada
A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.
- Conditions
- Leishmaniasis, Visceral
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 61
- Registration Number
- NCT00381394
- Locations
- 🇮🇳
GSK Investigational Site, Patna, India
Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.
- Conditions
- Malaria
- Interventions
- Biological: GSK malaria vaccine 257049 VaccineBiological: Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 894
- Registration Number
- NCT00380393
- Locations
- 🇹🇿
GSK Investigational Site, Amani, Tanga, Tanzania
A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00379990
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma
- Conditions
- AsthmaMild Asthma
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT00380354
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00380133
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, Lancashire, United Kingdom
Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults
- Conditions
- Influenza
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 660
- Registration Number
- NCT00380211
- Locations
- 🇺🇸
GSK Investigational Site, Burke, Virginia, United States